Cost-effectiveness of animal protein consumption in Turkey

被引:2
|
作者
Can, Mehmet Ferit [1 ]
Can, Hayriye Yesim [2 ]
机构
[1] Hatay Mustafa Kemal Univ, Fac Vet Med, Dept Anim Hlth Econ & Management, TR-31060 Antakya, Turkey
[2] Hatay Mustafa Kemal Univ, Fac Vet Med, Dept Food Hyg & Thchnol, Antakya, Turkey
来源
CIENCIA RURAL | 2022年 / 52卷 / 09期
关键词
animal; biological value; economic; food; protein content; DIETARY-PROTEIN; DAIRY; ADULTS; PLANT;
D O I
10.1590/0103-8478cr20210438
中图分类号
S3 [农学(农艺学)];
学科分类号
0901 ;
摘要
The most tangible economic indicator of animal protein consumption is the real price of 1 g protein of a certain quality. The present study aimed to determine and compare the cost-effectiveness of some animal proteins in Turkey. To determine cost-effectiveness, average protein contents (g/100 g). biological values (%), and inflation-adjusted 36-month real prices (TRY/kg) of eight different foods of animal origin were used. The ANOV4 test yielded a significant difference between the cost-effectiveness of selected animal proteins (P<0.01 and eta 2 = 0.973). Multiple comparisons revealed that chicken meat and chicken egg, between which there was no significant difference, were economically superior to other Pods < 0.05). Cow's milk and homogenized yogurt, between which there was no significant difference, took second place in terms of cost-effectiveness. These products were followed by fresh kashar cheese. ripened Turkish white cheese, beef meat, and mutton meat. There were also significant relationships between the unit prices of certain animal products. Although the real price of 1 g of animal protein varies according to time and place depending on the factors affecting supply and demand. the global economic advantage of egg and chicken meat coincides with the dimensions of health and religious beliefs. If today's demographic, climatic, biological. and technological developments can make animal protein production cheaper and more reliable, consumer welfare in underdeveloped and developing countries can increase.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Cost-effectiveness
    Radhakrishnan, Muralikrishnan
    Venkatesh, Rengaraj
    Ravindran, Ravilla D.
    OPHTHALMOLOGY, 2008, 115 (01) : 211 - 212
  • [32] Cost-effectiveness sensitivity to cost-effectiveness correlation: A simulation study
    Muston, D.
    VALUE IN HEALTH, 2008, 11 (03) : A175 - A175
  • [33] Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio
    Anthony O’Hagan
    John W. Stevens
    Jacques Montmartin
    PharmacoEconomics, 2000, 17 : 339 - 349
  • [34] Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio
    O'Hagan, A
    Stevens, JW
    Montmartin, J
    PHARMACOECONOMICS, 2000, 17 (04) : 339 - 349
  • [35] Cost-effectiveness analysis of escitalopram in the treatment of major depressive disorder in Turkey
    Hemels, ME
    Karamustafyoglu, O
    Ozmen, E
    Dilsad, S
    Mene, S
    VALUE IN HEALTH, 2005, 8 (03) : 392 - 392
  • [36] COST-EFFECTIVENESS OF EFMOROCTOCOG ALFA IN TREATMENT OF SEVERE HEMOPHILIA A PATIENTS IN TURKEY
    Tatar, M.
    Kamaci, E.
    Alhagiri, E.
    Alghamdi, M.
    VALUE IN HEALTH, 2023, 26 (12) : S102 - S102
  • [37] THE COST-EFFECTIVENESS OF DETECTING ARRHYTHMIAS WITH INSERTABLE CARDIAC MONITORS (ICM) IN TURKEY
    Saltik, Ozdemir Z.
    Tsintzos, S.
    Diamantopoulos, A.
    Quiroz, M.
    Scott, R. A.
    VALUE IN HEALTH, 2017, 20 (09) : A581 - A581
  • [38] COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
    Hagens, Arnold
    Inkaya, Ahmet Cagkan
    Yildirak, Kasirga
    Sancar, Mesut
    van der Schans, Jurjen
    Sancar, Aylin Acar
    Unal, Serhat
    Postma, Maarten
    Yegenoglu, Selen
    VACCINES, 2021, 9 (04)
  • [39] COST-EFFECTIVENESS OF AFLIBERCEPT IN THE TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION IN TURKEY
    Tunalioglu, A.
    Ozdemir, O.
    Eldem, B.
    Unlu, N.
    Alp, M. N.
    Saatci, A. O.
    Ozmert, E.
    Deger, C.
    Asan, S.
    Sumer, F.
    Parali, E.
    Ozel, M. O.
    Erdal, E.
    Sar, C.
    VALUE IN HEALTH, 2015, 18 (03) : A181 - A182
  • [40] COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY
    Tatar, M.
    Akbulut, H.
    VALUE IN HEALTH, 2009, 12 (07) : A222 - A222